{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:35:48Z","timestamp":1793172948178,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Diabetic macular edema (DME) is a leading cause of vision loss among patients with diabetes. Anti-VEGF agents such as aflibercept have long been the cornerstone of treatment, though frequent dosing imposes a significant burden. faricimab, a bispecific antibody targeting both VEGF-A and angiopoietin-2, has emerged as a novel alternative with the potential for extended durability. Evidence from Indian populations remains limited, warranting comparative evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This randomized controlled trial was conducted at a tertiary care institute from January 2024 to June 2025. Seventy-four treatment-na\u00efve DME patients were randomized equally to receive either intravitreal faricimab (6.0 mg) or aflibercept (2.0 mg). All patients received three loading doses at 4-week intervals followed by as-needed retreatment based on functional and anatomical criteria. Primary outcomes included changes in best-corrected visual acuity and central macular thickness at 48 weeks. Secondary outcomes were injection frequency and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Both groups were comparable at baseline. At 48 weeks, mean BCVA improvement was similar (AFL: \u20130.366 logMAR; FAR: \u20130.374 logMAR, p=NS). CMT reduction was equivalent between groups (AFL: \u2013119 \u00b5m; FAR: \u2013132 \u00b5m, p=NS). Faricimab achieved significantly longer mean dosing intervals (12.86 vs. 9.47 weeks, p&lt;0.001) with fewer injections required at maintenance phase. Safety profiles were similar, with only mild, transient adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Faricimab demonstrated equivalent efficacy and safety to aflibercept in treatment-na\u00efve Indian DME patients, with the added advantage of reduced injection burden and longer treatment intervals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2693_25","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:01:08Z","timestamp":1781712068000},"page":"1708-1713","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A randomized controlled study to compare the efficacy of intravitreal faricimab 6.0 mg versus aflibercept 2.0 mg in management of treatment-naive diabetic macular edema in Indian populations"],"prefix":"10.4103","volume":"74","author":[{"given":"Sanjay","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Army Hospital Research and Referral, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrida","family":"Dutt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Army Hospital Research and Referral, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Joshi","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Sati","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Dhar","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Avasthi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Army Hospital Research and Referral, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Khaleel","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Srujana","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Advanced Centre of Ophthalmic and Visual Sciences, Army Hospital (R&R), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","article-title":"Diabetic macular oedema","volume":"5","author":"Tan","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrendo.2016.53","article-title":"Diabetes mellitus and its complications in India","volume":"5","author":"Unnikrishnan","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.oret.2019.06.005","article-title":"Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema","volume":"3","author":"Sugimoto","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks for diabetic macular edema (YOSEMITE and RHINE): Primary phase 3 results","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for treatment resistant diabetic macular edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","article-title":"Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: Recent clinically relevant findings from DRCR. net Protocol T","volume":"28","author":"Cai","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","article-title":"Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: A systematic literature review and network meta-analysis","volume":"40","author":"Watkins","year":"2023","journal-title":"Adv Ther"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of faricimab in neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomized, double-masked, phase 3 trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"1374891","DOI":"10.1155\/2021\/1374891","article-title":"Comparisons of one to three monthly injections of aflibercept for diabetic macular edema by practical protocol","volume":"2021","author":"Hayashi","year":"2021","journal-title":"J Diabetes Res"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00417-022-05703-9","article-title":"Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes","volume":"260","author":"Sugimoto","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/APO.0000000000000634","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with diabetic macular edema: 1-year subgroup analysis of the phase III YOSEMITE and RHINE trials","volume":"12","author":"Ishida","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2693_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:12Z","timestamp":1793170812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2693_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2693_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2025-10-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}